AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026)
AbbVie's (ABBV) quarterly Goodwill & Intangibles came in at $84.7 billion in Q2 2026, down 8.64% year-over-year from $92.7 billion in Q2 2025, and down 2.06% quarter-over-quarter from $86.4 billion in Q1 2026.
Analysis
AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Goodwill & Intangibles for 15 consecutive years, with $84.7 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Goodwill & Intangibles fell 8.64% year-over-year to $84.7 billion in Q2 2026; TTM through Jun 2026 was $84.7 billion, a 8.64% decrease from a year earlier, with the FY2025 full-year figure at $88.3 billion, down 7.1% from the prior year.
- Goodwill & Intangibles was $84.7 billion for Q2 2026 at AbbVie, down from $86.4 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $106.3 billion in Q1 2022 and troughed at $84.7 billion in Q2 2026.
- A 5-year average of $94.6 billion and a median of $94.4 billion in 2024 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles climbed 12.4% in 2024 and fell 11.77% in 2025, its largest moves.
- Over 5 years, Goodwill & Intangibles stood at $99.6 billion in 2022, then decreased by 11.74% to $87.9 billion in 2023, then increased by 8.1% to $95.0 billion in 2024, then decreased by 7.1% to $88.3 billion in 2025, then retreated by 4.1% to $84.7 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $84.7 billion (Q2 2026), $86.4 billion (Q1 2026), and $88.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 84.66 Bn |
| Mar 31, 2026 | 86.44 Bn |
| Dec 31, 2025 | 88.28 Bn |
| Sep 30, 2025 | 89.94 Bn |
| Jun 30, 2025 | 92.67 Bn |
| Mar 31, 2025 | 93.77 Bn |
| Dec 31, 2024 | 95.02 Bn |
| Sep 30, 2024 | 101.94 Bn |
| Jun 30, 2024 | 93.63 Bn |
| Mar 31, 2024 | 95.65 Bn |
| Dec 31, 2023 | 87.90 Bn |
| Sep 30, 2023 | 90.69 Bn |
| Jun 30, 2023 | 95.09 Bn |
| Mar 31, 2023 | 97.07 Bn |
| Dec 31, 2022 | 99.60 Bn |
| Sep 30, 2022 | 100.45 Bn |
| Jun 30, 2022 | 103.85 Bn |
| Mar 31, 2022 | 106.28 Bn |
| Dec 31, 2021 | 108.33 Bn |
| Sep 30, 2021 | 109.75 Bn |